Search
GenScript
Atezolizumab Monoclonal Antibody (6B12)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Additional Information:
{{banner.description}}
FIGURE: 1 / 2
Atezolizumab Antibody (A01949-40) in ELISA
Standard curve of Atezolizumab Sandwich ELISA. The Atezolizumab Sandwich ELISA assay is developed by using Anti-Atezolizumab Antibody (10G9), mAb, Mouse (GenScript, A01948-40) and Anti-Atezolizumab Antibody (6B12), mAb, Mouse (GenScript, A01949-40) as capture and detection antibody, respectively. In this ELISA assay, Anti-Atezolizumab Antibody (6B12), mAb, Mouse (GenScript, A01949-40) was labeled with Biotin. GenScript can provide customized conjugation service for this product per customers request. The sensitivity of detecting Rituximab ... View More
Product Details
A01949-40
Product Specifications
Species Reactivity
Human
Host/Isotype
Mouse
/ IgG1, kappa
Class
Monoclonal
Type
Antibody
Clone
6B12
Immunogen
Atezolizumab
Conjugate
Form
Lyophilized
Amount
40 µg
Purification
Protein A
Storage buffer
PBS, pH 7.4
Contains
0.02% sodium azide
Storage conditions
-20°C, Avoid Freeze/Thaw Cycles
Shipping conditions
Ambient (domestic); Wet ice (international)
Product Specific Information
Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab blocks the interaction of PD-L1 with programmed cell death protein 1 (PD-1) and CD80 receptors (B7-1Rs). PD-L1 can be highly expressed on certain tumors, which is thought to lead to reduced activation of immune cells (cytotoxic T-cells in particular) that might otherwise recognize and attack the cancer. Inhibition of PD-L1 by atezolizumab can remove this inhibitor effect and thereby engender an anti-tumor response. It is one of several ways to block inhibitory signals related to T-cell activation, a more general strategy known as "immune checkpoint inhibition."
Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below.
Target Information
Programmed death receptor ligand 1 (PD-L1, also called B7-H1) is a recently described B7 family member. To date, one specific receptor has been identified that can be ligated by PD-L1. This receptor, programmed death receptor 1 (PD-1), has been shown to negatively regulate T-cell receptor (TCR) signaling. Upon ligating its receptor, PD-L1 has been reported to decrease TCR-mediated proliferation and cytokine production. PD-L1 expression was found to be abundant on many murine and human cancers and could be further up-regulated upon IFN-gamma stimulation. Thus, PD-L1 might play an important role in tumor immune evasion.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Have you cited this product in a publication?
Let us know so we can reference it here.
Bioinformatics
Protein Aliases: B7 homolog 1; B7-H1; B7-H1,PD-L1; CD274; CD274 antigen; costimulatory molecule; PD-L1; PDCD1 ligand 1; pdl-1; Programmed cell death 1 ligand 1; programmed death-1 ligand 1; sCD274; similar to Homo sapiens B7-1 and B7-2; soluble CD274; soluble PD L1; soluble PD-L1; B7-H1; sPD L1; unnamed protein product
Gene Aliases: B7-H; B7H1; CD274; hPD-L1; PD-L1; PDCD1L1; PDCD1LG1; PDL1
UniProt ID: (Human) Q9NZQ7
Entrez Gene ID: (Human) 29126
adaptive immune response
immune system process
negative regulation of T cell mediated immune response to tumor cell
immune response
signal transduction
cell surface receptor signaling pathway
T cell costimulation
negative regulation of interferon-gamma production
negative regulation of interleukin-10 production
positive regulation of interleukin-10 production
response to cytokine
TRIF-dependent toll-like receptor signaling pathway
positive regulation of T cell proliferation
negative regulation of T cell proliferation
positive regulation of transcription, DNA-templated
regulation of activated T cell proliferation
negative regulation of activated T cell proliferation
negative regulation of T cell activation
regulation of T cell apoptotic process
cellular response to lipopolysaccharide
negative regulation of tumor necrosis factor superfamily cytokine production
regulation of activated CD4-positive, alpha-beta T cell apoptotic process
positive regulation of activated CD8-positive, alpha-beta T cell apoptotic process
negative regulation of CD4-positive, alpha-beta T cell proliferation
negative regulation of CD8-positive, alpha-beta T cell activation
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Performance Guarantee
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support